A Nature Communications study reported that STING agonist 8803 inhibited tumor growth in human meningioma samples and reduced tumor volume and mortality in mouse models. Researchers found the STING pathway is expressed in both meningioma tumor cells and immune cells in the tumor microenvironment.
Northwestern Medicine researchers identified a potent immunotherapy approach targeting the STING pathway for meningiomas, the most common primary brain tumor. The experimental drug STING agonist 8803 triggered tumor cell death and immune responses in human samples and mouse models.
A study published in Science sequenced cancer-related genes in 493 cat tumor samples across 13 cancer types, revealing striking genetic similarities with human cancers and opening possibilities for shared treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06466720 |
Measuring and Mapping Cognitive Decline After Brain Radiosurgery |
ACTIVE_NOT_RECRUITING | |
| NCT02939833 |
Effects of Scalp Nerve Blocks on Systemic Inflammation |
UNKNOWN | NA |
| NCT02648997 |
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01880749 |
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas |
COMPLETED | EARLY_PHASE1 |
| NCT01655927 |
Efficacy of Tranexamic Acid in Brain Tumor Resections |
UNKNOWN | PHASE3 |
| NCT00517959 |
SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors |
UNKNOWN | PHASE3 |
